A new special series in JCO Oncology Practice, a journal of the American Society of Clinical Oncology (ASCO), explores the causes of disparities in cancer care and outcomes for Black people in the United States and examines potential solutions to begin to achieve health equity for this population.
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced plans to test a research site assessment tool and implicit bias training program, both of which are designed to address one of the barriers to clinical trial participation: trials not routinely being offered by clinicians to eligible patients.
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of the American Society of Clinical Oncology’s (ASCO) Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation.
As part of its ongoing efforts to increase the diversity of the oncology workforce, the American Society of Clinical Oncology (ASCO) is launching a new internship program for medical students from populations underrepresented in medicine (UIM)1, and today announced five medical schools across the country that have been selected to serve as hosts in the inaugural Oncology Summer Internship (OSI) program. The selected medical schools include: The Ohio State University; the University of Arizona Health Sciences College of Medicine – Tucson; the University of California San Francisco (UCSF); the University of Pittsburgh; and the University of Rochester.
The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients. The joint recommendations are detailed in a series of articles published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The series provides a comprehensive examination of eligibility criteria for cancer clinical trials with recommendations to address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal (GI) cancers. In recognition of this progress, the American Society of Clinical Oncology (ASCO) has named Molecular Profiling Driving Progress in Gastrointestinal Cancers as the Advance of the Year in Clinical Cancer Advances 2021 — just released today.
ALEXANDRIA, Va. – Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and white Americans have been selected to participate in the American Society of Clinical Oncology’s (ASCO) quality programs, including the Quality Oncology Practice Initiative (QOPI®) and Quality Training Program (QTP). Today ASCO and Susan G. Komen (Komen), with funding from the Fund II Foundation for each practice’s training and participation, announced the recipients. The three-year program, will be administered through Conquer Cancer, the ASCO Foundation.
“Fifty years after President Nixon signed the National Cancer Act to make cancer a national public health priority, we continue to see its lasting impact on progress against cancer as demonstrated by the 31% decline in overall cancer mortality between 1991-2018, driven largely by substantial reductions in lung cancer mortality related to a decline in smoking, improved screening and better treatment.
The American Society of Clinical Oncology (the Society), an affiliated organization of the Association for Clinical Oncology (the Association), collectively known as ASCO, submitted an amicus curiae brief in support of motions in four cases to enjoin the Most Favored Nation (MFN) Model from taking effect on January 1, 2021. The Society’s friend-of-the-court brief urges the courts to stop implementation of the model, citing its devastating impact on patients.
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) has elected Eric P. Winer, MD, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Five new members were also elected to the ASCO Board of Directors and the Nominating Committee.
As part of its ongoing commitment to addressing inequities in cancer care and research, the American Society of Clinical Oncology (ASCO) is launching a new educational series focused on the role of social determinants of health in cancer care and cancer outcomes. The free series, which kicks off today, will help educate oncology trainees and early career oncologists about social determinants of health and their impact on patients and cancer care.
Two-thirds of Americans report that their scheduled cancer screenings, such as mammograms and colonoscopies, have been delayed or skipped in the midst of the COVID-19 crisis, according to the American Society of Clinical Oncology (ASCO)’s fourth annual National Cancer Opinion Survey.
The American Society of Clinical Oncology released today a position statement that recommends specific actions for applying telemedicine in cancer care during the pandenic and after its expiration.
One of the nation’s leading cancer organizations today called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO), the American Society of Clinical Oncology (ASCO) argues that while progress has been made in raising awareness of disparities and driving research, the cancer community needs to take bolder, more aggressive steps to achieve equity for all patients.
The American Society of Clinical Oncology (ASCO) released a position statement that raises concerns about home infusion of anticancer therapy and Centers for Medicare & Medicaid Services (CMS) regulations regarding the practice.